Stock Updates

How has Alexion Pharmaceuticals, Inc.:(NASDAQ:ALXN) performed recently?

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) is a large market cap stock with a market cap of 30282.36. It is in the Biotechnology industry and sector Healthcare, with a current P/E of 328.35, a forward P/E of 21.69 and EPS of 0.4. At a stock price of 129.7 (0.22%) it has a dividend yield of *TBA.

EPS growth for the last five years have been 5.10%, more recently this last year it has grown by -79.50%. The next year growth is going to be about 28.64% and more long-term 18.28% after five years. EPS growth quarter over quarter is -38.80%. Sales growth for the past five years have been 36.90% and sales growth quarter over quarter is 18.40%.

For performance, Alexion Pharmaceuticals, Inc. the past week has seen a gain of -0.28%. For the last month performance for Alexion Pharmaceuticals, Inc. is -3.04%. While the last quarter is 1.73% and half year, 1.40%. Finally for the year, performance is -22.70%.

The 52-week high for Alexion Pharmaceuticals, Inc., is at -32.95%, and for the 52-week low it comes to a value of 17.31%. The 20-day simple moving average is 0.24% and -10.53% for the 200-day simple moving average.

Volatility for the week is at 3.50%, and for the month it is 2.73%. Alexion Pharmaceuticals, Inc., has a target price of 171.75.

In terms of debt, long term debt/equity is 0.39, and for total debt/equity Alexion Pharmaceuticals, Inc. has 0.4. The gross margin is 91.80%, while operating margin is 21.70%, the profit margin is 3.20%. The current ratio is 3.6 and the quick ratio is 3.1.

Insider ownership is at 0.50%, with instituitional ownership at 98.30%. Alexion Pharmaceuticals, Inc. has a payout ratio of 0.00%. With the total shares outstanding coming to 233.48. The shares float is 223.42, with the float short at 2.70%, with short ratio coming to 3.28.

In terms of returns, the return on assets see Alexion Pharmaceuticals, Inc., get 0.70%, with its returns on investment at 1.60%. Return on equity is 1.10%. So will the investors see the target price of 171.75, reached soon?

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.


About the author

Mark Hines

Leave a Comment